Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
Jayastu SenapatiTareq AbuasabFady Gh HaddadFarhad RavandiTapan Mahendra KadiaCourtney D D DiNardoNaval G DaverNaveen PemmarajuYesid AlvaradoMark A BrandtHagop M KantarjianGautam BorthakurPublished in: American journal of hematology (2022)